BAT’s nicotine pouch toxicant study: nine of eleven products were VELO
Short answer: A study in the peer-reviewed journal BMC Chemistry measured 132 analytes in eleven nicotine pouches and two snus products. According to the authors, the pouches contained more than 90 per cent lower levels than snus in most tests, and none exceeded the limits in the GOTHIATEK snus standard. But the study is not independent. Five of its six authors are BAT employees, and nine of the eleven pouches are BAT’s own VELO brand. The two competitor products are identified only as “CP1” and “CP2”. The study measures product content, not what users absorb and not health outcomes.

Who is behind the study
| Item | What the study states |
|---|---|
| Publication | BMC Chemistry 20, article 219, published 14 August 2026 (open access) |
| Authors | Simone Hadley, Belinda Zonnestein, Jana Jeffery, Yen Nguyen and Helena Digard, all at BAT (Investments) Limited in Southampton, and Kevin McAdam, McAdam Scientific Ltd |
| Contact | The lead author, with a bat.com email address |
| Pouches tested | Nine VELO products from Nicoventures Trading Ltd (BAT) and two competitor products, CP1 (“Mini, Mint”, 8 mg) and CP2 (“Slim Spearmint”, 9 mg), with no brand names |
| Comparators | The 1S4 reference snus (University of Kentucky) and General Classic Blend White Portion Large (Swedish Match), bought in 2022. For cigarette smoke, published values for the 1R6F reference cigarette are used, with no new measurements |
| Laboratories | Including Eurofins (US and Sweden) and Labstat (Canada) |
The study does not explain why these two competitor products were chosen. The General snus brand is now owned by Philip Morris International through Swedish Match, BAT’s biggest rival in pouches. In other words, BAT chose both its own products and the products they are compared with.
We have not been able to read the journal’s funding and competing-interests declaration in full. With five of six authors employed by BAT, we assume BAT paid for the study, but we have not confirmed this.
What the study shows
According to the abstract, 70 of the 132 analytes could not be quantified in any of the products. 58 analytes were quantifiable in snus and 47 in the pouches. 15 were found only in snus and four only in one or more pouches. The authors write that the pouches contained more than 90 per cent lower levels than snus “in most tests”, and that no pouch exceeded GOTHIATEK, Swedish Match’s voluntary quality standard for snus.
The table also shows that the picture is not uniform. The values below are the lowest and highest per pouch among the products in which the analyte could be quantified.
| Analyte | Nicotine pouches | Snus |
|---|---|---|
| Tobacco-specific nitrosamines (NNN, NNK, NAT, NAB) | Not detected in any pouch | NNN 226–262 ng, NNK 75–79 ng |
| Nickel | Quantifiable in 5 of 11, highest 85.7 ng | 620–756 ng |
| Lead | Quantifiable in 1 of 11, 26.9 ng | 99–127 ng |
| Formaldehyde | Quantifiable in all 11, 0.33–2.69 µg | 1.01–1.17 µg |
| Ethyl carbamate | Quantifiable in 3 of 11, highest 66.8 ng | Highest 13.5 ng |
| Acrolein | Quantifiable in 2 of 11, highest 0.28 µg | Not quantifiable |
| NDBzA (nitrosamine) | Quantifiable in 1 of 11, 3.3 ng | Not detected |
| Nicotine | 5.4–20.3 mg | 5.9–7.2 mg |
The highest formaldehyde level in a pouch was more than twice that in snus, and ethyl carbamate, acrolein and NDBzA were found in some pouches but not, or at lower levels, in snus. The study reports this, but it does not show in the “more than 90 per cent lower” headlines.
The authors’ conclusion is carefully worded: the results “support the hypothesis” that exclusive use of nicotine pouches “might offer a potentially reduced risk alternative” relative to continued smoking, and “comparable or even less risk” than snus.
What the study does not show
- Health effects. The study measures what is in the product. It does not measure how much is released in the mouth, what is absorbed by the body, or any health outcomes.
- The wider market. Eleven products, nine of them from one manufacturer, say little about the hundreds of pouch brands sold in Europe and the US.
- Independent confirmation. The results need to be replicated by researchers with no link to a manufacturer, using products chosen by someone other than BAT.
Why the study is surfacing now
The study was published in August 2026 but only spread in the trade press in mid-November, including through VapeBrief. That coincides with the delay of the European Commission’s proposal for a new Tobacco Products Directive (TPD3), and with nicotine pouch taxation returning to Ecofin in December. Manufacturers’ own measurement data become arguments in that debate. See TPD3 and nicotine pouches and VELO’s FDA authorization.
Our assessment
- The measurements carry weight, but the selection is BAT’s. External laboratories and a peer-reviewed journal suggest the figures hold. A manufacturer choosing its own products and anonymising competitors makes it hard to conclude anything beyond VELO.
- “More than 90 per cent lower” is a summary, not the full picture. For some analytes, individual pouches had higher levels than snus.
- For the industry, this shows what is required. Anyone wanting to make claims about product content needs to disclose selection, laboratories and all results, including those that cut the other way.
Frequently asked questions
Was the study done by BAT? Five of six authors are BAT employees, and nine of the eleven pouches tested are BAT’s VELO.
Does the study show nicotine pouches are harmless? No. It measures content, not health effects, and the authors themselves speak of a hypothesis.
Which competitor products were tested? It is not stated. They are called CP1 and CP2.
Primary sources
- Hadley et al., Toxicant contents of oral nicotine pouches: comparative quantitative analysis with Swedish snus and cigarette smoke, BMC Chemistry 20:219, 14 August 2026
- The same study in PubMed Central (PMC13753406)
- Oral nicotine pouch study finds toxicants more than 90% below snus in most tests, 14 November 2026 — VapeBrief
Want to know how to disclose your products’ content in a way that holds up?
Book an initial call